WEKO3
アイテム
{"_buckets": {"deposit": "da221851-93e8-4177-9937-5aa044d6f386"}, "_deposit": {"created_by": 2, "id": "5649", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "5649"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00005649", "sets": ["9"]}, "author_link": ["24009", "24010", "24012", "24013", "24016", "24008", "24011", "24005", "24006", "24015", "24014", "24007"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2014-07-05", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageStart": "142", "bibliographicVolumeNumber": "14", "bibliographic_titles": [{"bibliographic_title": "BMC Neurology"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Background: Since there has been no conclusive evidence regarding the treatment of ocular myasthenia, treatment guidelines were recently issued by the European Federation of Neurological Societies/European Neurological Society (EFNS/ENS). However, the therapeutic outcomes concerning the quality-of-life (QOL) of patients with ocular myasthenia are not yet fully understood.Methods: We investigated the therapeutic outcomes of patients with purely ocular myasthenia in a multicenter cross-sectional survey in Japan. To evaluate the severity of ocular symptoms, we used the ocular-quantitative MG (QMG) score advocated by Myasthenia Gravis Foundation of America. We used the Japanese translated version of the MG-QOL15, a self-appraised scoring system.Results: Of 607 myasthenia gravis (MG) patients with an observation-duration of illness ? 2 years, the cases of 123 patients (20%) were limited to ocular muscles (purely ocular myasthenia). During the entire clinical course, 81 patients experienced both ptosis and diplopia, 36 had ptosis alone, and six had diplopia alone. Acetyl-cholinesterase inhibitors and prednisolone were used in 98 and 52 patients, respectively. Treatment improved ocular symptoms, with the mean reduction in ocular-QMG score of 2.3 ± 1.8 points. However, 47 patients (38%) failed to gain minimal manifestation or a better status. Patients with unfavorable outcomes also self-reported severe QOL impairment. Multivariate analyses showed that the pretreatment ocular-QMG score was associated with unfavorable outcomes, but not associated with the patient\u0027s QOL.Conclusion: A treatment strategy designed in accord with a patient\u0027s ocular presentation must be considered in order to improve ocular symptoms and the patient\u0027s QOL.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "BMC Neurology, 14(1), 142; 2014", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "BioMed Central"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1186/1471-2377-14-142", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "c 2014 Suzuki et al.; licensee BioMed Central Ltd."}, {"subitem_rights": "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated."}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "14712377", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Suzuki, Shigeaki"}], "nameIdentifiers": [{"nameIdentifier": "24005", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Murai, Hiroyuki"}], "nameIdentifiers": [{"nameIdentifier": "24006", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Imai, Tomihiro"}], "nameIdentifiers": [{"nameIdentifier": "24007", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nagane, Yuriko"}], "nameIdentifiers": [{"nameIdentifier": "24008", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Masuda, Masayuki"}], "nameIdentifiers": [{"nameIdentifier": "24009", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsuda, Emiko"}], "nameIdentifiers": [{"nameIdentifier": "24010", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Konno, Shingo"}], "nameIdentifiers": [{"nameIdentifier": "24011", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Oji, Satoru"}], "nameIdentifiers": [{"nameIdentifier": "24012", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakane, Shunya"}], "nameIdentifiers": [{"nameIdentifier": "24013", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Motomura, Masakatsu"}], "nameIdentifiers": [{"nameIdentifier": "24014", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Suzuki, Norihiro"}], "nameIdentifiers": [{"nameIdentifier": "24015", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Utsugisawa, Kimiaki"}], "nameIdentifiers": [{"nameIdentifier": "24016", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-21"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "BMCNeu14_142.pdf", "filesize": [{"value": "442.6 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 442600.0, "url": {"label": "BMCNeu14_142.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/5649/files/BMCNeu14_142.pdf"}, "version_id": "df6e2f9a-a98b-48de-8d0c-1d671ebfa571"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Ocular myasthenia", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Ocular-quantitative myasthenia gravis score", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Quality-of-life", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Therapeutic outcome", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Quality of life in purely ocular myasthenia in Japan", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Quality of life in purely ocular myasthenia in Japan"}]}, "item_type_id": "2", "owner": "2", "path": ["9"], "permalink_uri": "http://hdl.handle.net/10069/34731", "pubdate": {"attribute_name": "公開日", "attribute_value": "2014-10-01"}, "publish_date": "2014-10-01", "publish_status": "0", "recid": "5649", "relation": {}, "relation_version_is_last": true, "title": ["Quality of life in purely ocular myasthenia in Japan"], "weko_shared_id": -1}
Quality of life in purely ocular myasthenia in Japan
http://hdl.handle.net/10069/34731
http://hdl.handle.net/10069/347311ce89c00-631e-4256-af92-cf79fabe6330
名前 / ファイル | ライセンス | アクション |
---|---|---|
BMCNeu14_142.pdf (442.6 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2014-10-01 | |||||
タイトル | ||||||
タイトル | Quality of life in purely ocular myasthenia in Japan | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Ocular myasthenia | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Ocular-quantitative myasthenia gravis score | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Quality-of-life | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Therapeutic outcome | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Suzuki, Shigeaki
× Suzuki, Shigeaki× Murai, Hiroyuki× Imai, Tomihiro× Nagane, Yuriko× Masuda, Masayuki× Tsuda, Emiko× Konno, Shingo× Oji, Satoru× Nakane, Shunya× Motomura, Masakatsu× Suzuki, Norihiro× Utsugisawa, Kimiaki |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Background: Since there has been no conclusive evidence regarding the treatment of ocular myasthenia, treatment guidelines were recently issued by the European Federation of Neurological Societies/European Neurological Society (EFNS/ENS). However, the therapeutic outcomes concerning the quality-of-life (QOL) of patients with ocular myasthenia are not yet fully understood.Methods: We investigated the therapeutic outcomes of patients with purely ocular myasthenia in a multicenter cross-sectional survey in Japan. To evaluate the severity of ocular symptoms, we used the ocular-quantitative MG (QMG) score advocated by Myasthenia Gravis Foundation of America. We used the Japanese translated version of the MG-QOL15, a self-appraised scoring system.Results: Of 607 myasthenia gravis (MG) patients with an observation-duration of illness ? 2 years, the cases of 123 patients (20%) were limited to ocular muscles (purely ocular myasthenia). During the entire clinical course, 81 patients experienced both ptosis and diplopia, 36 had ptosis alone, and six had diplopia alone. Acetyl-cholinesterase inhibitors and prednisolone were used in 98 and 52 patients, respectively. Treatment improved ocular symptoms, with the mean reduction in ocular-QMG score of 2.3 ± 1.8 points. However, 47 patients (38%) failed to gain minimal manifestation or a better status. Patients with unfavorable outcomes also self-reported severe QOL impairment. Multivariate analyses showed that the pretreatment ocular-QMG score was associated with unfavorable outcomes, but not associated with the patient's QOL.Conclusion: A treatment strategy designed in accord with a patient's ocular presentation must be considered in order to improve ocular symptoms and the patient's QOL. | |||||
書誌情報 |
BMC Neurology 巻 14, 号 1, p. 142, 発行日 2014-07-05 |
|||||
出版者 | ||||||
出版者 | BioMed Central | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 14712377 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1186/1471-2377-14-142 | |||||
権利 | ||||||
権利情報 | c 2014 Suzuki et al.; licensee BioMed Central Ltd. | |||||
権利 | ||||||
権利情報 | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | BMC Neurology, 14(1), 142; 2014 |